Search results for "Lipoprotein"

showing 10 items of 982 documents

Prolonged sleep restriction induces changes in pathways involved in cholesterol metabolism and inflammatory responses

2016

Article

0301 basic medicineMaleEpidemiologyPhysiologychemistry.chemical_compoundinsufficient sleep0302 clinical medicineHigh-density lipoproteinFinlandSleep restrictionGENERAL-POPULATIONINSULIN-RESISTANCEeducation.field_of_studyMultidisciplinarytulehdusCARDIOVASCULAR RISKGLUCOSE-METABOLISMta3142Chronic inflammationMiddle AgedSleep in non-human animals3. Good healthSleep deprivationCholesterolMetabolomeFemalemedicine.symptomAdultmedicine.medical_specialtyACUTE-PHASE RESPONSELIVER-X-RECEPTORSPopulationBiologyta3111Articlesleep restriction03 medical and health sciencesInsulin resistanceMetabolic DiseasesInternal medicinemedicineMetabolomeHumansCORONARY-HEART-DISEASEeducationLiver X receptorDyslipidaemiasAgedCASSETTE TRANSPORTER G1Gene Expression Profilingta1182ta3121medicine.diseaseSleep deprivation030104 developmental biologyEndocrinologychemistryinflammationcholesterol metabolismSleep Deprivation3111 BiomedicineGene expressionHIGH-DENSITY-LIPOPROTEIN030217 neurology & neurosurgeryBlood Chemical AnalysisScientific Reports
researchProduct

Clinical and biochemical characteristics of individuals with low cholesterol syndromes: A comparison between familial hypobetalipoproteinemia and fam…

2017

Background The most frequent monogenic causes of low plasma cholesterol are familial hypobetalipoproteinemia (FHBL1) because of truncating mutations in apolipoprotein B coding gene (APOB) and familial combined hypolipidemia (FHBL2) due to loss-of-function mutations in ANGPTL3 gene. Objective A direct comparison of lipid phenotypes of these 2 conditions has never been carried out. In addition, although an increased prevalence of liver steatosis in FHBL1 has been consistently reported, the hepatic consequences of FHBL2 are not well established. Methods We investigated 350 subjects, 67 heterozygous carriers of APOB mutations, 63 carriers of the p.S17* mutation in ANGPTL3 (57 heterozygotes and …

0301 basic medicineMaleHepatic steatosisSettore MED/09 - Medicina InternaApolipoprotein BEndocrinology Diabetes and Metabolism030204 cardiovascular system & hematologymedicine.disease_causeANGPTL3 gene; APOB gene; Familial combined hypolipidemia; Familial hypobetalipoproteinemia; HDL cholesterol; Hepatic steatosis; Low cholesterol syndromesHypobetalipoproteinemiasExon0302 clinical medicineHDL cholesterolANGPTL3Nutrition and DieteticFamilial hypobetalipoproteinemiaGeneticsMutationNutrition and Dieteticsbiologyhepatic steatosisHomozygoteANGPTL3 geneMiddle AgedLow cholesterol syndromesPhenotypePhenotypelipids (amino acids peptides and proteins)FemaleCardiology and Cardiovascular MedicineANGPTL3 gene; APOB gene; familial combined hypolipidemia; familial hypobetalipoproteinemia; HDL cholesterol; hepatic steatosis; low cholesterol syndromesmedicine.medical_specialtyHeterozygoteLow cholesterol syndromeHepatic steatosi03 medical and health sciencesInternal medicineInternal MedicinemedicineHumansAPOB geneFamilial combined hypolipidemiaGeneAgedAngiopoietin-Like Protein 3Apolipoproteins Bbusiness.industryHeterozygote advantagemedicine.disease030104 developmental biologyEndocrinologyAngiopoietin-like ProteinsMutationbiology.proteinlow cholesterol syndromesSteatosisbusiness
researchProduct

The Mediterranean Diet decreases LDL atherogenicity in high cardiovascular risk individuals: a randomized controlled trial.

2017

cope Traditional Mediterranean diet (TMD) protects against cardiovascular disease through several mechanisms such as decreasing LDL cholesterol levels. However, evidence regarding TMD effects on LDL atherogenic traits (resistance against oxidation, size, composition, cytotoxicity) is scarce. Methods and results We assessed the effects of a 1-year intervention with a TMD on LDL atherogenic traits in a random sub-sample of individuals from the PREDIMED study (N = 210). We compared two TMDs: one enriched with virgin olive oil (TMD-VOO, N = 71) and another with nuts (TMD-Nuts, N = 68), versus a low-fat control diet (N = 71). After the TMD-VOO intervention, LDL resistance against oxidation incre…

0301 basic medicineMaleRiskmedicine.medical_specialtyMediterranean diet030204 cardiovascular system & hematologyDiet MediterraneanDecreasing ldllaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled triallawInternal medicineMedicineHumansNutsParticle SizeCells CulturedAged030109 nutrition & dieteticsbusiness.industryCholesterolLDL Particle SizeDietary patternMiddle AgedAtherosclerosisPredimedLipoproteins LDLstomatognathic diseasesEndocrinologychemistryCardiovascular Diseaseslipids (amino acids peptides and proteins)Femalebusinesshuman activitiesFood ScienceBiotechnologyOlive oilMolecular nutritionfood research
researchProduct

Simultaneous Inhibition of Peripheral CB1R and iNOS Mitigates Obesity-Related Dyslipidemia Through Distinct Mechanisms.

2020

Diabetic dyslipidemia, characterized by increased plasma triglycerides and decreased HDL cholesterol levels, is a major factor contributing to nonalcoholic steatohepatitis and cardiovascular risk in type 2 diabetes. Activation of the cannabinoid-1 receptor (CB1R) and activation of inducible nitric oxide synthase (iNOS) are associated with nonalcoholic steatohepatitis progression. Here, we tested whether dual-targeting inhibition of hepatic CB1R and iNOS improves diabetic dyslipidemia in mice with diet-induced obesity (DIO mice). DIO mice were treated for 14 days with (S)-MRI-1867, a peripherally restricted hybrid inhibitor of CB1R and iNOS. (R)-MRI-1867, the CB1R-inactive stereoisomer that …

0301 basic medicineMaleVery low-density lipoproteinEndocrinology Diabetes and MetabolismNitric Oxide Synthase Type II[SDV.BC.IC] Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB][SDV.BBM.BM] Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologyMice0302 clinical medicineReceptor Cannabinoid CB1[SDV.BC.IC]Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB]Receptor[SDV.BBM.BC] Life Sciences [q-bio]/Biochemistry Molecular Biology/Biochemistry [q-bio.BM]Cells Cultured[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismbiology[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism[SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry Molecular Biology/Biomolecules [q-bio.BM]Nitric oxide synthaseLiver[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyKexinlipids (amino acids peptides and proteins)medicine.medical_specialty[SDV.OT]Life Sciences [q-bio]/Other [q-bio.OT]LipoproteinsImmunoblotting030209 endocrinology & metabolismReal-Time Polymerase Chain Reaction03 medical and health sciencesInternal medicineCommentariesInternal MedicinemedicineAnimalsObesity[SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry Molecular Biology/Biochemistry [q-bio.BM]Dyslipidemiasbusiness.industry[SDV.OT] Life Sciences [q-bio]/Other [q-bio.OT]PCSK9nutritional and metabolic diseases[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologymedicine.diseaseLipid Metabolism[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMice Inbred C57BL030104 developmental biologyEndocrinologyGlucoseLDL receptorbiology.proteinHepatocytes[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologySteatosisbusinessDyslipidemia
researchProduct

An in-depth analysis shows a hidden atherogenic lipoprotein profile in non-diabetic chronic kidney disease patients

2019

Background: Chronic kidney disease (CKD) is an independent risk factor for atherosclerotic disease. We hypothesized that CKD promotes a proatherogenic lipid profile modifying lipoprotein composition and particle number. Methods: Cross-sectional study in 395 non-diabetic individuals (209 CKD patients and 186 controls) without statin therapy. Conventional lipid determinations were combined with advanced lipoprotein profiling by nuclear magnetic resonance, and their discrimination ability was assessed by machine learning. Results: CKD patients showed an increase of very-low-density (VLDL) particles and a reduction of LDL particle size. Cholesterol and triglyceride content of VLDLs and intermed…

0301 basic medicineMaleVery low-density lipoproteinMagnetic Resonance SpectroscopyClinical BiochemistryMachine LearningPCSK9chemistry.chemical_compound0302 clinical medicineLp(a)Risk FactorsDrug DiscoveryProspective Studiesmedicine.diagnostic_testMiddle AgedLipids030220 oncology & carcinogenesisMolecular MedicineFemalelipids (amino acids peptides and proteins)Proprotein Convertase 9Adultmedicine.medical_specialtylipoprotein subfractionsLipoproteins03 medical and health sciencesInternal medicinemedicineHumansRisk factorRenal Insufficiency ChronicAgedPharmacologybusiness.industryCholesterolPCSK9dyslipidemiamedicine.diseaseAtherosclerosis030104 developmental biologyEndocrinologyCross-Sectional StudieschemistryCase-Control StudiesbusinessLipid profileDyslipidemiachronic kidney diseaseLipoproteinKidney disease
researchProduct

Dietary protein restriction reduces circulating VLDL triglyceride levels via CREBH-APOA5-dependent and -independent mechanisms

2018

Hypertriglyceridemia is an independent risk factor for cardiovascular disease. Dietary interventions based on protein restriction (PR) reduce circulating triglycerides (TGs), but underlying mechanisms and clinical relevance remain unclear. Here, we show that 1 week of a protein-free diet without enforced calorie restriction significantly lowered circulating TGs in both lean and diet-induced obese mice. Mechanistically, the TG-lowering effect of PR was due, in part, to changes in very low-density lipoprotein (VLDL) metabolism both in liver and peripheral tissues. In the periphery, PR stimulated VLDL-TG consumption by increasing VLDL-bound APOA5 expression and promoting VLDL-TG hydrolysis and…

0301 basic medicineMalemedicine.medical_specialtyVery low-density lipoproteinDietary proteinFGF21Calorie restrictionmTORC1Lipoproteins VLDLMechanistic Target of Rapamycin Complex 1Protein Serine-Threonine Kinases03 medical and health sciencesMice0302 clinical medicineRisk FactorsInternal medicinemedicineDiet Protein-RestrictedIntegrated stress responseAnimalsHumansCyclic AMP Response Element-Binding ProteinTriglyceridesRandomized Controlled Trials as TopicHypertriglyceridemiaChemistryHydrolysisHypertriglyceridemianutritional and metabolic diseasesGeneral Medicinemedicine.diseaseLipid Metabolism030104 developmental biologyEndocrinologyApolipoproteinsHypotriglyceridemiaLiverApolipoprotein A-Vlipids (amino acids peptides and proteins)Female030217 neurology & neurosurgeryLipoproteinResearch Article
researchProduct

Gut Microbiome Associates With Lipid-Lowering Effect of Rosuvastatin in Vivo

2018

Source at https://doi.org/10.3389/fmicb.2018.00530 . Background: Statin has been widely used to treat hyperlipidemia because of its high potency in decreasing cholesterol levels. The present study aimed to examine the lipid-lowering effect of rosuvastatin and the composition, diversity and species abundance of gut microbiome in association with rosuvastatin efficacy. TRIAL REGISTRATION: ChiCTR-ORC-17013212 at the First Affiliated Hospital of Dalian Medical University, November 2, 2017. Results:Totally 64 patients with hyperlipidemia were treated with 10 mg/day of rosuvastatin for 4-8 weeks. Blood lipid indicators triglycerides (TG), total cholesterol (TC), high density lipoprotein (HDL), lo…

0301 basic medicineMicrobiology (medical)Statinmedicine.drug_classlcsh:QR1-502PhysiologyBlood lipidsgut microbiomeBiologyGut floraMicrobiologylcsh:Microbiology03 medical and health scienceschemistry.chemical_compoundHigh-density lipoproteinHyperlipidemiamedicinehyperlipidemiaRosuvastatinVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Cardiology: 771VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Kardiologi: 771CholesterolVDP::Medical disciplines: 700::Basic medical dental and veterinary science disciplines: 710::Pharmacology: 728nutritional and metabolic diseasesFusobacteriaVDP::Medical disciplines: 700::Basic medical dental and veterinary science disciplines: 710::Medical microbiology: 715medicine.diseasebiology.organism_classification16S rRNA sequencing030104 developmental biologychemistryVDP::Medisinske Fag: 700::Basale medisinske odontologiske og veterinærmedisinske fag: 710::Medisinsk mikrobiologi: 715VDP::Medisinske Fag: 700::Basale medisinske odontologiske og veterinærmedisinske fag: 710::Farmakologi: 728lipids (amino acids peptides and proteins)hypolipidemic effectrosuvastatinmedicine.drugFrontiers in Microbiology
researchProduct

2018

Recent studies suggest that exercise alters the gut microbiome. We determined whether six-weeks endurance exercise, without changing diet, affected the gut metagenome and systemic metabolites of overweight women. Previously sedentary overweight women (n = 19) underwent a six-weeks endurance exercise intervention, but two were excluded due to antibiotic therapy. The gut microbiota composition and functions were analyzed by 16S rRNA gene amplicon sequencing and metagenomics. Body composition was analyzed with DXA X-ray densitometer and serum metabolomics with NMR metabolomics. Total energy and energy-yielding nutrient intakes were analyzed from food records using Micro-Nutrica software. Serum…

0301 basic medicineMicrobiology (medical)Very low-density lipoproteinbiologyCholesterolPhysiologyAkkermansia030229 sport sciencesGut floraOverweightbiology.organism_classificationMicrobiology03 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicinechemistryEndurance trainingmedicineAndroid fat distributionMicrobiomemedicine.symptomFrontiers in Microbiology
researchProduct

The mitochondria-targeted antioxidant MitoQ modulates oxidative stress, inflammation and leukocyte-endothelium interactions in leukocytes isolated fr…

2016

It is not known if the mitochondria-targeted antioxidants such as mitoquinone (MitoQ) can modulate oxidative stress and leukocyte-endothelium interactions in T2D patients. We aimed to evaluate the beneficial effect of MitoQ on oxidative stress parameters and leukocyte-endothelium interactions in leukocytes of T2D patients. The study population consisted of 98 T2D patients and 71 control subjects. We assessed metabolic and anthropometric parameters, mitochondrial reactive oxygen species (ROS) production, glutathione peroxidase 1 (GPX-1), NFκB-p65, TNFα and leukocyte-endothelium interactions. Diabetic patients exhibited higher weight, BMI, waist circumference, SBP, DBP, glucose, insulin, HOMA…

0301 basic medicineMitochondrial ROSMaleGPX1Antioxidantendocrine system diseasesUbiquinonemedicine.medical_treatmentBMI body mass indexClinical BiochemistryLDL low density lipoprotein cholesterolAnti-Inflammatory AgentsTPP triphenylphosphonium030204 cardiovascular system & hematologyPharmacologymedicine.disease_causeBiochemistryMitoQAntioxidantschemistry.chemical_compound0302 clinical medicineGlutathione Peroxidase GPX1IR insulin resistanceLeukocyteslcsh:QH301-705.5chemistry.chemical_classificationlcsh:R5-920AnthropometryChemistryGlutathione peroxidaseType 2 diabetesMiddle AgedFemalemedicine.symptomlcsh:Medicine (General)Research PaperPMN polymorphonuclear leukocyteshs-CRP high-sensitive C-reactive proteinHOMA-IR homeostasis model assessment of insulin resistanceInflammationT2D type 2 diabetes03 medical and health sciencesOrganophosphorus CompoundsmedicineDBP diastolic blood pressure HbA1c glycated hemoglobinHUVEC human umbilical vein endothelial cellsHumansEndotheliumAgedInflammationReactive oxygen speciesMitoQGlutathione PeroxidaseTumor Necrosis Factor-alphaSBP systolic blood pressureOrganic ChemistryTranscription Factor RelAnutritional and metabolic diseasesHDL high density lipoprotein cholesterolOxidative Stress030104 developmental biologylcsh:Biology (General)Diabetes Mellitus Type 2ImmunologyReactive Oxygen SpeciesOxidative stressRedox Biology
researchProduct

Lipid levels, atrial fibrillation and the impact of age:Results from the LIPIDOGRAM2015 study

2020

Background and aims: An inverse relationship between lipid levels and atrial fibrillation (AF) has been suggested, but whether the association is upheld for all age groups remains unclear. The aim of the study was to examine associations between lipid levels and AF by age groups in a nationwide study in Poland. Methods: Multivariate Poisson regression models were used to estimate prevalence ratios (PRs) for AF by lipid levels. Low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), total cholesterol (TC), non-HDL-C and LDL-C/HDL-C ratios were grouped into quartiles. Results: Of the 13,724 participants, 5.2% (n = 708) had AF. People with…

0301 basic medicineMultivariate statisticsmedicine.medical_specialtyInverse AssociationEpidemiology030204 cardiovascular system & hematology03 medical and health sciencessymbols.namesake0302 clinical medicineAgeAge groupsRisk FactorsTotal cholesterolInternal medicineAtrial FibrillationmedicinePrevalenceHumansPoisson regressionTriglyceridesLipoprotein cholesterolbusiness.industryCholesterol HDLAtrial fibrillationCholesterol LDLmedicine.diseaseAtrial fibrillationLipids030104 developmental biologyCholesterolQuartilesymbolsCardiologylipids (amino acids peptides and proteins)PolandCardiology and Cardiovascular Medicinebusiness
researchProduct